Q4 beat, stock slips intraday: JNJ.DE Johnson & Johnson XETRA 21 Jan 2026

Johnson & Johnson reported a fourth-quarter beat and raised 2026 guidance, yet JNJ.DE stock is trading lower intraday on 21 Jan 2026. The company posted adjusted quarterly EPS above estimates and stronger-than-expected sales in Innovative Medicines. Investors reacted to mixed signals: durable product growth but headline legal and tariff noise. We review the numbers, drivers and what to watch next for the XETRA-listed shares.

JNJ.DE stock Q4 results and market reaction

Johnson & Johnson reported adjusted quarterly earnings of €2.46 per share and revenue of €24.56 billion for Q4. The company beat Street estimates and gave 2026 sales guidance above consensus. The stock opened at €185.62 and sits at €179.68 intraday, down €7.48 or -3.99%. Volume is 10,802 versus an average of 3,602, showing elevated trading interest.

JNJ.DE stock financials and valuation metrics

JNJ.DE shows trailing EPS of €8.91 and a trailing PE of 20.81. Market capitalization stands near €446.73 billion. The 50-day average price is €176.80 and the 200-day average is €153.21, signalling medium-term strength. Key ratios include ROE 32.69%, dividend yield about 2.39%, and debt to equity 0.08, reflecting an elite balance sheet.

JNJ.DE stock guidance, product drivers and outlook

Management forecast 2026 operational sales of $99.5 billion to $100.5 billion, above consensus. Growth was driven by Darzalex blood cancer sales and Tremfya psoriasis performance. Stelara faced biosimilar pressure, but excluding Stelara the portfolio grew near 14%–15% according to management. Tariff and talc litigation commentary add headline risk despite stronger core sales.

JNJ.DE stock technicals and short-term trading picture

Technicals show RSI at 51.93 and MACD slightly negative, indicating neutral momentum. Bollinger Band middle sits at €176.59 with upper band €181.49. The stock trades above its 50-day moving average but near intraday support at €178.24. Short-term traders should note ATR €2.79, meaning daily swings remain moderate relative to price.

Meyka AI rates JNJ.DE with a score out of 100

Meyka AI rates JNJ.DE with a score out of 100: 71.86/100 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects strong cash flow metrics, high ROE, and solid guidance offset by valuation above some peers and legal and tariff uncertainties.

JNJ.DE stock risks and opportunities

Key upside drivers include Darzalex momentum, MedTech resilience, and margin recovery in Innovative Medicines. Key risks include litigation outcomes, tariff exposure on devices, and Stelara biosimilar pressure. Currency moves and U.S. pricing agreements could impact reported sales and profits. Investors should weigh yield, low leverage, and near-term headline volatility.

Final Thoughts

Johnson & Johnson delivered a Q4 beat and raised 2026 guidance, yet JNJ.DE stock trades down intraday as the market weighs legal and tariff headlines against product momentum. The firm’s trailing PE of 20.81 and EPS €8.91 support a premium valuation given high ROE and cash generation. Meyka AI’s forecast model projects a near-term price of €184.28, implying an upside of +2.56% from the current €179.68. The model also shows a longer‑term yearly projection of €151.18, implying downside of -15.86%. Forecasts are model‑based projections and not guarantees. Monitor Darzalex sales, device tariffs, and upcoming guidance updates for intraday catalysts. For live data and tools, see our Meyka AI stock page for JNJ.DE and the linked earnings coverage.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.